anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. A pharmaceutical composition comprising: (a) an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof; (b) an amount of a statin or a pharmaceutically acceptable salt thereof, where said statin is selected from the group comprising fluvastatin, rivastatin and and simvastatin, and (c. a pharmaceutically acceptable carrier or diluent. 2. A composition of claim 1 comprising amlodipine besylate. 3. A pharmaceutical composition of claim 2, wherein said statin is fluvastatin. 4. A pharmaceutical composition of claim 2, wherein said statin is rivastin. 5. A pharmaceutical composition of claim 2, wherein said statin is simvastatin. 6. A kit for achieving a therapeutic effect in a mammal comprising: (a). an amount of amlodipine or a pharmaceutically acceptable acid addtion salt thereof and a pharmaceutically acceptable carrier or diluent in a first unit dosage form; (b). an amount of a statin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and (c). container means for containing said first and second dosage forms; provided that said statin is not atorvastatin or a pharmaceutically acceptable salt thereof. 7. A kit of claim 6 comprising amlodipine besylate. 8. A method for treating a mammal in need of therapeutic treatment comprising administering to said mammal (a) an amount of a first compound, said first compound being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and (b) an amount of a second compound, said second compound being statin or a pharmaceutically acceptable salt thereof; wherein said statin is selected from the group comprising fluvastatin, rivastatin and and simvastatin, wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable canier or diluent. 9. A method of claim 8 comprising amlodipine besylate. 10. The method of claim 9, wherein said statin is selected from the group comprising fluvastatin, rivastatin and and simvastatin. 11. The method of claim 8 wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment. 12. The method of claim 8 wherein said therapeutic treatment comprises antianginal treatment. 13. The method of claim 8 wherein said therapeutic treatment comprises cardiac risk management. 14. The method of claim 8 wherein said therapeutic treatment comprises antiatherosclerotic treatment.
The invention discloses novel application of Prunella vulgaris Linn. or an extract thereof. The novel application of the Prunella vulgaris Linn. or the extract thereof is angiogenesis inhibition; and the Prunella vulgaris Linn. or the extract thereof has a broad application prospect in the treatment of vascular dysplasia diseases such as rheumatoid disease, tumor, retina eyeground disease, psoriasis and the like. The invention provides a novel content and a novel direction for the development, application and research of the medicine, and also provides a novel means for the research on the treatment of vascular dysplasia diseases by Chinese medicines.
All patients received a SC injection of 30 mg KZR-616 at Visit 1 (Day 1), followed by weekly SC injections of 45 mg KZR-616 up to a maximum of 96 weeks. Study drug administration ended for all patients in Study KZR-616-003E when the last patient enrolled completed 48 weeks of dosing.
Infused intravenously over 10 minutes upon umbilical cord clamping. First 10 assigned patients received 2 grams per protocol. Subsequent 13 patients received 1.5 grams, dose recalibrated per protocol.
The invention discloses lactobacillus plantarum capable of inhibiting clostridium nucleatum and improving halitosis, and belongs to the technical field of microorganisms. The Lactobacillus plantarum CCFM1214 is preserved in the Guangdong province microbial strain preservation center in 2021, 12 and 17 days, and the preservation address is No. 59, No. 5, No. 59 of the Michelia Tokyo 100, Guangzhou city, and the preservation number is GDMCC No. 62140. The Lactobacillus plantarum can remarkably inhibit or reduce the formation of Clostridium nucleatum biofilm, reduce the amount of VSCs produced by the Lactobacillus plantarum, improve halitosis in vivo, and reduce the risk of halitosis occurrence and development.
PURPOSE:To obtain a new compound useful especially as a therapeutic agent for schizophrenia, having strongly blocking action on dopamine receptor and weak alpha blocking action as adverse action. CONSTITUTION:A compound of formula I (R is 2,3-dichlorophenyl) or its salt such as 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbosty ril. The compound of formula I is obtained by reacting a compound of formula II (X<1> is a halogen or a group such as mesyloxy or tosyloxy to cause the same substitution reaction as that of a halogen) with a compound of formula III in the absence of a solvent or in an inert solvent (e.g. dioxane) in the presence of a base (e.g. potassium hydroxide) at room temperature to 200 deg.C. The base compound is used as a dehydrohalogenating agent and optionally an alkali metal iodide compound is added as a reaction promoter to carry out the reaction. A dose of the compound of formula I is 0.1-10mg/kg/day.
The invention relates to a sucrose fatty acid ester embedded type cationic liposome genetic vector system, a preparing method thereof and applications of the method. The genetic vector system is a composition comprising genetic materials and liposomes formed from cationic lipoids and sucrose esters adopted as auxiliary lipoids. The cationic lipoids comprise peptide type cationic lipoids, gemini cationic lipoids and quaternary ammonium salt type cationic lipoids. The sucrose esters comprise sucrose stearate, sucrose palmitate, sucrose laurate, sucrose oleate and sucrose erucate. The vector can effectively compress plasmid DNA and siRNA and is capable of efficient transfection in vitro and in vivo and nearly free of toxicity for cells and mice. The genetic vector system has a good research and application prospect in gene therapy.
OBJECTIVES: This study aims to gather and analyze the anatomical characteristics of the posterior gastric artery (PGA), investigate the presence and metastasis of lymph nodes around the PGA in patients with gastric cancer. Additionally, the study aims to analyze the relationship between the PGA and its surrounding lymph nodes and the clinicopathological features of patients with gastric cancer.
METHODS: This study consisted of a cross-sectional analysis of data from 52 patients with gastric cancer who underwent total or proximal gastrectomy at the Department of Gastrointestinal Surgery, First Affiliated Hospital of Dalian Medical University, between January 2020 and November 2022. Intraoperative exploration was performed to determine the presence of the PGA, and patients with the PGA were assessed for relevant anatomical characteristics, including the length of the PGA and the distance from the root of the PGA to the celiac trunk. Dissection of lymph nodes around the PGA was also performed. Statistical methods were employed to describe and analyze the data regarding the presence of the PGA, as well as the presence and metastasis of the lymph nodes around the PGA. Additionally, the study identified clinicopathological factors associated with these conditions.
RESULTS: The PGA was identified in 39 (75.0%) out of 52 patients with gastric cancer, exhibiting a mean PGA length of 3.5 ± 0.8 cm and a mean distance from the root of the PGA to the celiac trunk of 6.7 ± 1.7 cm. Among the 39 patients who underwent dissection of lymph nodes around the PGA, 36 lymph nodes around the PGA were detected in 20 patients. Analysis of factors associated with the presence of lymph nodes around the PGA revealed a significant correlation with the macroscopic type of the tumor and the total number of dissected lymph nodes (P = 0.007 and P = 0.022, respectively), with a larger number of total dissected lymph nodes being an independent factor (OR = 1.105, 95%CI: 1.019-1.199, P = 0.016). Furthermore, analysis of risk factors for metastasis of the lymph nodes around the PGA demonstrated that the total number of metastatic lymph nodes, No.3 lymph node metastasis, and No.11 lymph node metastasis were associated with metastasis of the lymph nodes around the PGA (P = 0.043, P = 0.028, and P = 0.020, respectively).
CONCLUSION: The PGA exhibits a high incidence. It is essential to carefully identify the PGA during procedures involving the PGA and consider appropriate preservation or disconnection of this vessel. The presence of lymph nodes around the PGA is not an isolated occurrence. Gastric cancer can result in metastasis of the lymph nodes around the PGA. Although the overall risk of metastasis of the lymph nodes around the PGA is low in patients with gastric cancer, it increases in the presence of conditions such as No.3 lymph node metastasis, No.11 lymph node metastasis, advanced tumor stage, and extensive metastases in other regional lymph nodes.
Firearm injuries are a significant cause of morbidity and mortality for children and teens. Access to firearms has been associated with suicide completion in the pediatric mental health population. Current practice in our pediatric Emergency Department (ED) and inpatient psychiatric unit is to screen all mental health patients for firearm access, and to recommend safe firearm storage practices. However, there is no data on the baseline rate of safe firearm storage device use in the homes of these patients, or on the effectiveness of providing these recommendations during hospitalization.

This study has two phases, a baseline and an intervention. During the baseline phase, the research team will study whether there is an improvement in safe firearm storage device use in the homes of participants 7 or 30 days after safe storage practices are recommended during an ED or inpatient psychiatric visit. During the intervention phase, in addition to the standard recommendation of safe storage practices during the visit, the research team will distribute firearm safety storage devices such as a lock box, trigger lock, and and/or cable lock to families at the time of study enrollment. The investigators will study whether there is an improvement in safe firearm storage device use in the homes of intervention participants after 7 or 30 days compared to the usual care group.
Since 2021, a novel strain of goose reovirus (GRV) has emerged within the goose farming industry in Guangdong province, China. This particular viral variant is distinguished by the presence of white necrotic foci primarily localized in the liver and spleen, leading to substantial economic losses for the poultry industry. However, the etiology, prevalence and genomic characteristics of the causative agent have not been thoroughly investigated. In this study, we conducted an epidemiological inquiry employing suspected GRV samples collected from May 2021 to September 2022. The macroscopic pathological and histopathological lesions associated with GRV-infected clinical specimens were examined. Moreover, we successfully isolated the GRV strain and elucidated the complete genome sequence of the isolate GD21/88. Through phylogenetic and recombination analysis, we unveiled that the GRV strains represent a novel variant resulting from multiple reassortment events. Specifically, the μNS, λC, and σNS genes of GRV were found to have originated from chicken reovirus, while the σA gene of GRV exhibited a higher degree of similarity with a novel duck reovirus. The remaining genes of GRV were traced back to Muscovy duck reovirus. Collectively, our findings underscore the significance of GRV as a pathogenic agent impacting the goose farming industry. The insights gleaned from this study contribute to a more comprehensive understanding of the epidemiology of GRV in Southern China and shed light on the genetic reassortment events exhibited by the virus.
The present invention is a semen coicis health care powder which takes semen coicis as main raw material. The present invention is a health product which is made of semen coicis together with other grains. The health product is prepared mainly aiming at solving the problems in the existing health care foods of having single nutrition and having no prevention and treatment function to fatness, hypertension, hyperlipidemia, hyperglycemia, visual deterioration and so on. The weight ratio of the materials is: semen coicis 90-95 percent, cassia seed 1-2 percent, buckwheat rice 1.5-3 percent, peanut kernel 0.5-1 percent and black glutinous rice 2-4 percent. Firstly, the materials are separately cooked, and mixed, crushed, packed; secondly, the materials are processed radiation sterilization by cobalt 60, and finally, the product is made. The present invention has the advantages of that each person should eat the powder 25g twice a day separately at morning and at evening; after long-term eating, the powder can prevent and cure fatness, hypertension, hyperlipidemia, hyperglycemia and visual deterioration.
The invention discloses a preparation method of a targeted controlled release arsenical medicine. The preparation process comprises three steps: preparation of an arsenical medicine-loaded magnetic Fe3O4 core, coating of the magnetic arsenical medicine by nanosilicon dioxide and biocompatibility of the arsenical medicine. According to the preparation method disclosed by the invention, the arsenical medicine and porous magnetic Fe3O4 are coprecipitated and the arsenical medicine is adsorbed on the surface of the magnetic Fe3O4, so that the release speed is delayed. The arsenical medicine is coated by using porous nanosilicon dioxide so as to realize targeted long-acting release and controlled release of the arsenical medicine. Surface treatment is carried out on the arsenical medicine by using a polyvinylpyrrolidone macromolecular sol, so that the biocompatibility is improved. The preparation method disclosed by the invention can be used for solving the problem that an existing controlled release arsenical medicine preparation process is complex and unstable in release speed, and can be used for realizing targeted delivery, reducing the side effects of the medicine and improving the curative effect.
The invention discloses an application of an OXPHOS inhibitor as an antitumor drug Alisertib synergist. The inventor finds out through research that the breast cancer cells treated by the Alisertib present a dependent state on oxidative phosphorylation and related signal paths. Treatment with Alisertib rapidly reduces ATP levels in mitotic phase M cells. OXPHOS inhibitor treatment can enhance the tumor killing effect of Alisertib in a variety of cell lines. The inventors have found that OXPHOS inhibitors in combination with Alisertib further reduce ATP levels in M cells, prolonging mitotic time and the probability of cell death during mitosis. In a mouse experiment, the inventor finds that the combination of the Alisertib and the metformin can obviously inhibit the growth of the tumor in a gastric lavage mode, and the tumor inhibition efficiency is obviously improved compared with that of a single medicine, without causing obvious weight reduction of the mouse. The researches show that the combination of the oxidative phosphorylation inhibitor metformin and the Alisertib can effectively improve the tumor inhibition efficiency and enhance the killing effect, and meanwhile, the side effect is low.
Exploration of the incidence and outcomes of Acute Kidney Injury (AKI) broadly, and sepsis associated AKI specifically, in Aboriginal and Torres Strait Islander (First Nations) people has been limited. We compared a nested cohort of First Nations people drawn from a multinational randomised controlled trial of hydrocortisone in septic shock, to a cohort matched for age, sex and severity of illness. Acute Kidney Injury was defined using the Kidney Disease Improving Global Outcomes (KDIGO) criteria, as well as incident use of kidney replacement therapy (KRT). Major Adverse Kidney Events (MAKE) were described as the composite of death, new dialysis requirement or persisting kidney dysfunction at hospital discharge. A cohort of 57 Aboriginal and/or Torres Strait Islander patients with septic shock was identified. 91.2% (52) of the First Nations cohort met KDIGO criteria for Stage 1 AKI or greater and 63% (36) met Stage 3 criteria. 59.6% (34) of the First Nations required dialysis as compared to 45.6% (26) in the matched cohort. 60.7% (34) of First Nations participants met criteria for MAKE at hospital discharge. The proportions requiring dialysis at 6, 12 and 24 months were 8.3%, 9.1% and 6.9% respectively. The incidences of AKI and MAKE reported in this First Nations cohort are substantially higher than in previously published cohorts of patients with sepsis, even those that use sensitive definitions of AKI. Measures to promote better management of infectious diseases in First Nations communities are required.
INTRODUCTION: Acute Respiratory Distress Syndrome (ARDS) is a heterogeneous form of lung injury with severe hypoxemia and bilateral infiltrates after an inciting event that results in diffuse lung inflammation with a high mortality rate. While research in COVID-related ARDS has resulted in several pharmacotherapeutic agents that have undergone successful investigation, non-COVID ARDS studies have not resulted in many widely accepted pharmacotherapeutic agents despite exhaustive research.
AREAS COVERED: The aim of this review is to discuss adjuvant pharmacotherapies targeting non-COVID Acute Lung Injury (ALI)/ARDS and novel therapeutics in COVID associated ALI/ARDS. In ARDS, variable data may support selective use of neuromuscular blocking agents, corticosteroids and neutrophil elastase inhibitors, but are not yet universally used. COVID-ALI/ARDS has data supporting the use of IL-6 monoclonal antibodies, corticosteroids, and JAK inhibitor therapy.
EXPERT OPINION: Although ALI/ARDS modifying pharmacological agents have been identified in COVID-related disease, the data in non-COVID ALI/ARDS has been less compelling. The increased use of more specific molecular phenotyping based on physiologic parameters and biomarkers, will ensure equipoise between groups, and will likely allow more precision in confirming pharmacological agent efficacy in future studies.
AMONDYS 45 is supplied in single-dose vials as a preservative-free concentrated solution that requires dilution prior to administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use aseptic technique. 

  1. Calculate the total dose of AMONDYS 45 to be administered based on the patient's weight and the recommended dose of 30 milligrams per kilogram. Determine the volume of AMONDYS 45 needed and the correct number of vials to supply the full calculated dose. 
  2. Allow the vials to warm to room temperature. Mix the contents of each vial by gently inverting 2 or 3 times. Do not shake. 
  3. Visually inspect each vial of AMONDYS 45. The solution is a clear to slightly opalescent, colorless liquid, and may contain trace amounts of small, white to off-white amorphous particles. Do not use if the solution in the vials is cloudy, discolored or contains extraneous particulate matter other than trace amounts of small, white to off-white amorphous particles. 
  4. With a syringe fitted with a 21-gauge or smaller bore non-coring needle, withdraw the calculated volume of AMONDYS 45 from the appropriate number of vials. To avoid dulling the needle and fragmenting the stoppers, replace the needle periodically during preparation. 
  5. Dilute the withdrawn AMONDYS 45 in 0.9% Sodium Chloride Injection, USP, to make a total volume of 100 to 150 mL. Gently invert 2 to 3 times to mix. Do not shake. Visually inspect the diluted solution. Do not use if the solution is cloudy, discolored or contains extraneous particulate matter other than trace amounts of small, white to off-white amorphous particles. 
  6. Administer the diluted solution via an in-line 0.2 micron filter. 
  7. AMONDYS 45 contains no preservatives and should be administered immediately after dilution. Complete infusion of diluted AMONDYS 45 within 4 hours of dilution. If immediate use is not possible the diluted product may be stored for up to 24 hours at 2 °C to 8 °C (36 °F to 46 °F). Do not freeze. Discard unused AMONDYS 45.
INTRODUCTION: Ventilator-associated pneumonia (VAP) is associated with increased mortality, prolonged mechanical ventilation, and longer intensive care unit stays. The rate of VAP (VAPs per 1000 ventilator days) within a hospital is an important quality metric. Despite adoption of preventative strategies, rates of VAP in injured patients remain high in trauma centers. Here, we report variation in risk-adjusted VAP rates within a statewide quality collaborative.
METHODS: Using Michigan Trauma Quality Improvement Program data from 35 American College of Surgeons-verified Level I and Level II trauma centers between November 1, 2020 and January 31, 2023, a patient-level Poisson model was created to evaluate the risk-adjusted rate of VAP across institutions given the number of ventilator days, adjusting for injury severity, physiologic parameters, and comorbid conditions. Patient-level model results were summed to create center-level estimates. We performed observed-to-expected adjustments to calculate each center's risk-adjusted VAP days and flagged outliers as hospitals whose confidence intervals lay above or below the overall mean.
RESULTS: We identified 538 VAP occurrences among a total of 33,038 ventilator days within the collaborative, with an overall mean of 16.3 VAPs per 1000 ventilator days. We found wide variation in risk-adjusted rates of VAP, ranging from 0 (0-8.9) to 33.0 (14.4-65.1) VAPs per 1000 d. Several hospitals were identified as high or low outliers.
CONCLUSIONS: There exists significant variation in the rate of VAP among trauma centers. Investigation of practices and factors influencing the differences between low and high outlier institutions may yield information to reduce variation and improve outcomes.
FIELD: organic chemistry. SUBSTANCE: invention relates to derivatives of piperazine of the general formula (I)   where A is an alkylene chain with 1 or 2 carbon atoms; Z - dihydrobenzodioxynyl radical possibly substituted with dihydroxy-(C 1-4 )-alkyl; R - hydrogen; R 1  - phenyl; R 2  and R 3  together with nitrogen atom to which they both bound form saturated C 3-10 -heterocyclic ring, or their pharmaceutically acceptable salts. Compounds are synthesized by alkylation of compound of the formula (II)   with an alkylating agent of the formula X-A-CHR 1 CONR 2 R 3  where X - halogen, or alkyl-, or arylsulfonylhydroxy-group to be removed. Compounds of the formula (I) show effect on central nervous system by binding with 5-HT 1A  receptors and can be used for treatment of patients with CNS disorders. EFFECT: improved method of synthesis, enhanced effectiveness of compounds. 6 cl, 9 ex
PURPOSE:The titled preparation that is made by laminating a film containing drugs with another film containing a foaming agent and arranging outer films on both sides, thus suspending in the stomach after oral administration, to release the drugs gradually and keep the concentration enough to manifest remedial effect for hours. CONSTITUTION:The outerlayer film consisting of cellulose lower alkyl ether (A), polyacrylic acid or its salt (B) and a plasticizer, the innerlayer film-I consisting of A or A and B, a plasticizer and drugs, the innerlayer film-II consisting of A, B and a foaming agent such as a carbonate or bicarbonate or a mixture thereof with an organic acid are laminated in the order of the outerlayer film, the innerlayer film-I, the innerlayer film-2 and the outerlayer film. A is hydroxypropylcellulose, preferably having 3-10,000cps viscosity at 20 deg.C in 2% aqueous solution at a weight ratio of 10 A: (1-1,000) B. The amount of the foaming agent is 0.1-40pts.wt. per 10pts. of A and B mixture.